Immunic, Inc. (NASDAQ:IMUX - Get Free Report) saw unusually large options trading on Tuesday. Investors acquired 2,229 call options on the company. This represents an increase of approximately 849% compared to the typical daily volume of 235 call options.
Immunic Trading Down 3.2 %
IMUX stock traded down $0.04 during mid-day trading on Friday, hitting $1.20. The stock had a trading volume of 653,857 shares, compared to its average volume of 604,174. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11. The firm has a market capitalization of $108.09 million, a P/E ratio of -0.98 and a beta of 1.89. The firm has a fifty day simple moving average of $1.08 and a 200 day simple moving average of $1.21.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in IMUX. Jane Street Group LLC boosted its holdings in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after purchasing an additional 38,553 shares in the last quarter. HB Wealth Management LLC bought a new stake in shares of Immunic during the 4th quarter worth $81,000. State Street Corp boosted its stake in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company's stock valued at $276,000 after buying an additional 11,642 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock valued at $169,000 after buying an additional 42,383 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Immunic in the third quarter valued at about $50,000. 51.82% of the stock is owned by institutional investors.
Analysts Set New Price Targets
IMUX has been the subject of several research reports. William Blair assumed coverage on Immunic in a report on Tuesday. They set an "outperform" rating for the company. StockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a report on Thursday, March 20th. D. Boral Capital reiterated a "buy" rating and issued a $17.00 price objective on shares of Immunic in a research note on Wednesday, February 26th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Immunic in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $12.67.
Check Out Our Latest Stock Analysis on Immunic
About Immunic
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Recommended Stories
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
